HistoSonics’ Edison System Gains Limited UK Access, While Awaiting CE Marking

CEO Mike Blue Said Histotripsy Will Deliver Clinical Value At A Sustainable Cost For The NHS

 
• By Shubham Singh
  
HistoSonics’ Edison histotripsy system received US Food and Drug Administration (FDA) de novo clearance in October 2023 for treating liver tumors.

More from Strategy

More from Business